Nateglinide

209 interactions 492 cited references
Also sold as: Starlix®
About Nateglinide

Nateglinide is used alone or in combination with other medications to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) in people whose diabetes cannot be controlled by diet and exercise alone. Nateglinide belongs to a class o… Read the full Nateglinide drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ensitrelvir Abiraterone Acetate Insulin Glulisine (Rdna Origin) Injection Chloroquine Ofloxacin Otic Letermovir Injection
1 Contraindicated 95 Major 112 Moderate 1 Minor
All (209) Contraindicated (1) Major (95) Moderate (112) Minor (1)

Moderate

Nateglinide Quinapril Accupril An increased risk of hypoglycemia Details Nateglinide Ramipril Altace An increased risk of hypoglycemia Details Nateglinide Rasagiline Azilect An increased risk of hypoglycemia Details Nateglinide Rifampin Rifadin Reduced hypoglycemic action of nateglinide Details Nateglinide Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Nateglinide Ritonavir Norvir Worsening glycemic control Details Nateglinide Safinamide Xadago An increased risk of hypoglycemia Details Nateglinide Saquinavir Worsening glycemic control Details Nateglinide Saxagliptin Onglyza Increased risk of hypoglycemia Details Nateglinide Selegiline Anipryl An increased risk of hypoglycemia Details Nateglinide Sitagliptin Brynovin An increased risk of hypoglycemia Details Nateglinide Sotagliflozin Inpefa An increased risk of hypoglycemia Details Nateglinide Sotalol Betapace Hypoglycemia or hyperglycemia; decreased symptoms of hypoglycemia Details Nateglinide Sparsentan Filspari Reduced CYP2C9 substrate exposure and reduced efficacy of CYP2C9 substrate Details Nateglinide St John's Wort Reduced hypoglycemic action of nateglinide Details Nateglinide Sulfacetamide Increased risk of hypoglycemia Details Nateglinide Sulfadiazine Microsulfon® Increased risk of hypoglycemia Details Nateglinide Sulfadoxine Increased risk of hypoglycemia Details Nateglinide Sulfaguanidine Increased risk of hypoglycemia Details Nateglinide Sulfamerazine Increased risk of hypoglycemia Details Nateglinide Sulfamethazine Increased risk of hypoglycemia Details Nateglinide Sulfamethizole Increased risk of hypoglycemia Details Nateglinide Sulfanilamide Increased risk of hypoglycemia Details Nateglinide Sulfapyridine Increased risk of hypoglycemia Details Nateglinide Sulfathiazole Increased risk of hypoglycemia Details Nateglinide Sulfisoxazole Increased risk of hypoglycemia Details Nateglinide Telaprevir Worsening glycemic control Details Nateglinide Timolol Betimol Hypoglycemia or hyperglycemia; decreased symptoms of hypoglycemia Details Nateglinide Tipranavir Aptivus Worsening glycemic control Details Nateglinide Tirzepatide Mounjaro Increased risk of hypoglycemia Details Nateglinide Trandolapril Mavik® An increased risk of hypoglycemia Details Nateglinide Tranylcypromine Parnate An increased risk of hypoglycemia Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.